1. |
Toumpanakis CG, Caplin ME. Molecular genetics of gastroenteropancreatic neuroendocrine tumors[J]. Am J Gastroenterol, 2008, 103(3):729-732.
|
2. |
Soga J. Early-stage carcinoids of the gastrointestinal tract:an analysis of 1 914 reported cases[J]. Cancer, 2005, 103(8):1587-1595.
|
3. |
Srirajaskanthan R, Shanmugabavan D, Ramage JK. Carcinoid syndrome[J]. BMJ, 2010, 341:c3941.
|
4. |
Shebani KO, Souba WW, Finkelstein DM, et al. Prognosis and survival in patients with gastrointestinal tract carcinoid tumors[J]. Ann Surg, 1999, 229(6):815-821.
|
5. |
Modlin IM, Moss SF, Chung DC, et al. Priorities for improvingthe management of gastroenteropancreatic neuroendocrine tumors[J]. J Natl Cancer Inst, 2008, 100(18):1282-1289.
|
6. |
Ramage JK, Ahmed A, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)[J]. Gut, 2012, 61(1):6-32.
|
7. |
Oberndorfer S, Karzinoide tumoren des dünndarms[J]. Frankf Z Pathol, 1907, 1:426-432.
|
8. |
Klöppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors:the WHO classification[J]. Ann N Y Acad Sci, 2004, 1014:13-27.
|
9. |
Jensen RT, Berna MJ, Bingham DB, et al. Inherited pancreatic endocrine tumor syndromes:advances in molecular pathogenesis, diagnosis, management, and controversies[J]. Cancer, 2008, 113(7 Suppl):1807-1843.
|
10. |
Turaga KK, Kvols LK. Recent progress in the understanding,diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors[J]. CA Cancer J Clin, 2011, 61(2):113-132.
|
11. |
中国胃肠胰神经内分泌肿瘤病理专家组. 中国胃肠胰神经内分泌肿瘤病理学诊断共识[J]. 中华病理学杂志, 2011, 40(4):257-262.
|
12. |
徐建明, 杨晨. 胃肠胰腺神经内分泌肿瘤国际诊断共识的解读[J]. 临床肿瘤学杂志, 2011, 16(11):1033-1038.
|
13. |
Rindi G, Klöppel G, Couvelard A, et al. TNM staging of midgutand hindgut (neuro) endocrine tumors:a consensus proposal including a grading system[J]. Virchows Arch, 2007, 451(4):757-762.
|
14. |
Klöppel G, Couvelard A, Perren A, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors:towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification[J]. Neuroendocrinology, 2009, 90(2):162-166.
|
15. |
Gastrointestinal Pathology Study Group of Korean Society of Pathologists; Cho MY, Kim JM, et al. Current trends of the incidence and pathological diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Korea 2000-2009:multicenter study[J]. Cancer Res Treat, 2012, 44(3):157-165.
|
16. |
Leja J, Essaghir A, Essand M, et al. Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas[J]. Mod Pathol, 2009, 22(2):261-272.
|
17. |
Tormey WP, Fitzgerald RJ. The clinical and laboratory correlates of an increased urinary 5-hydroxyindoleacetic acid[J]. Postgrad Med J, 1995, 71(839):542-545.
|
18. |
Oberg K, Eriksson B. Nuclear medicine in the detection, stagingand treatment of gastrointestinal carcinoid tumours[J]. Best Pract Res Clin Endocrinol Metab, 2005, 19(2):265-276.
|
19. |
Ghevariya V, Malieckal A, Ghevariya N, et al. Carcinoid tumors of the gastrointestinal tract[J]. South Med J, 2009, 102(10):1032-1040.
|
20. |
Coates SW Jr, Demarco DC. Metastatic carcinoid tumor discovered by capsule endoscopy and not detected by esophagogastroduodenoscopy[J]. Dig Dis Sci, 2004, 49(4):639-641.
|
21. |
Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system[J]. Ann Oncol, 2004, 15(6):966-973.
|
22. |
Nikolaou A, Thomas D, Kampanellou C, et al. The value of 11C-5-hydroxy-tryptophan positron emission tomography in neuroendocrine tumor diagnosis and management:experience from one center[J]. J Endocrinol Invest, 2010, 33(11):794-799.
|
23. |
Modlin IM, Tang LH. Approaches to the diagnosis of gut neuroendocrine tumors:the last word (today)[J]. Gastroenterology,.
|
24. |
Oberg K. Interferon in the management of neuroendocrine GEP-tumors:a review[J]. Digestion, 2000, 62 Suppl 1:92-97.
|
25. |
Kunz PL, Fisher GA. Advances in the treatment of gastroenteropancreatic neuroendocrine tumors[J]. Clin Exp Gastroenterol, 2010, 3(1):79-86.
|
26. |
Fendrich V, Bartsch DK. Surgical treatment of gastrointestinal neuroendocrine tumors[J]. Langenbecks Arch Surg, 2011, 396(3):299-311.
|
27. |
Stinner B, Kisker O, Zielke A, et al. Surgical management for carcinoid tumors of small bowel, appendix, colon, and rectum[J]. World J Surg, 1996, 20(2):183-188.
|
28. |
Sutton R, Doran HE, Williams EM, et al. Surgery for midgut carcinoid[J]. Endocr Relat Cancer, 2003, 10(4):469-481.
|
29. |
Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents[J]. Ann Oncol, 2006, 17(12):1733-1742.
|
30. |
Mejias M, Garcia-Pras E, Tiani C, et al. The somatostatin analogue octreotide inhibits angiogenesis in the earliest, but not in advanced, stages of portal hypertension in rats[J]. J Cell Mol Med, 2008, 12(5A):1690-1699.
|
31. |
Bruns C, Lewis I, Briner U, et al. SOM230:a novel somatostatinpeptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile[J]. Eur J Endocrinol, 2002, 146(5):707-716.
|
32. |
Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors[J]. J Clin Oncol, 2005, 23(12):2754-2762.
|
33. |
Kulke MH, Kim H, Clark JW, et al. A phase Ⅱ trial of gemcitabine for metastatic neuroendocrine tumors[J]. Cancer, 2004, 101(5):934-939.
|
34. |
Oberg K, Norheim I, Lundqvist G, et al. Cytotoxic treatment in patients with malignant carcinoid tumors. Response to streptozocin——alone or in combination with 5-FU[J]. Acta Oncol, 1987, 26(6):429-432.
|
35. |
Eriksson J, Stålberg P, Nilsson A, et al. Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors[J]. World J Surg, 2008, 32(5):930-938.
|
36. |
Le Treut YP, Delpero JR, Dousset B, et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report[J]. Ann Surg, 1997, 225(4):355-364.
|
37. |
Sutcliffe R, Maguire D, Ramage J, et al. Management of neuroendocrine liver metastases[J]. Am J Surg, 2004, 187(1):39-46.
|
38. |
Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low to intermediate-grade neuroendocrine tumors:results of a phase Ⅱstudy[J]. J Clin Oncol, 2008, 26(26):4311-4318.
|
39. |
, 112(2):583-590.
|